Cover Image
市場調查報告書

停經後骨質疏鬆症治療藥的全球市場:2016-2020年

Global Postmenopausal Osteoporosis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 358019
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
停經後骨質疏鬆症治療藥的全球市場:2016-2020年 Global Postmenopausal Osteoporosis Drugs Market 2016-2020
出版日期: 2016年05月11日 內容資訊: 英文 60 Pages
簡介

骨頭有成長及自然治癒的功能,不過,飲食和運動等級,產生生物化學反應變化的話,會導致骨質密度的變化,引發骨質疏鬆症。這個疾病,特徵是低骨骼密度及骨組織結構劣化,使得骨頭脆弱化。急速骨吸收和緩慢的骨置換可導致疾病的發展。性別、年齡、體型大小 (低體重) 、種族、家族史也影響骨質疏鬆症的發展。其他風險因素,有服用藥,鈣及維他命攝取,酒精攝取,抽煙等。骨骼強度的維持,雌激素 (女性荷爾蒙物質) 有重要作用,女性比男性更暴露於骨質疏鬆症風險。少量的骨質流失是正常的高齡化過程的一環,不過,更年期時雌激素等級急劇下降,會使骨質疏鬆症風險增大。停經後骨質疏鬆症治療藥的全球市場,預計今後到2020年以4.02%的年複合成長率擴大。

本報告以停經後骨質疏鬆症治療藥的全球市場為焦點,提供其現狀及2016-2020年的各藥效分類、治療線及地區 (北、中南美,亞太地區,歐洲、中東、非洲) 變化,來自產業專業資訊為基礎的市場推動要素,課題,趨勢,主要加入企業相關的調查、分析資訊。

第1章 摘要整理

  • 焦點

第2章 報告的範圍

  • 市場概要
  • 主要企業銷售產品

第3章 市場調查的方法

  • 取材方式
  • 經濟指標

第4章 簡介

  • 市場的主要特徵

第5章 疾病概要

  • 理解停經後骨質疏鬆症
  • 流行病學和人口動態
  • 風險因素
  • 症狀
  • 診斷
  • 治療

第6章 主要購買標準

第7章 開發情形

  • TBRIA
  • Romosozumab (AMG785)
  • Odanacatib (MK-0822)
  • Abaloparatide SC/Abaloparatide transdermal patch
  • PHN-031 (PH3)
  • NB S101
  • Teriparatide ZP Patch (ZP-PTH)
  • Blosozumab (LY2541546)

第8章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔 - 各治療分類

  • 再吸收抑制劑
  • 合成代謝藥

第10章 市場區隔 - 各治療線

第11章 地區市場區隔

  • 停經後骨質疏鬆症治療藥的全球市場 - 各地區:2015-2020年
  • 北、中南美的停經後骨質疏鬆症治療藥市場
  • 歐洲、中東、非洲的停經後骨質疏鬆症治療藥市場
  • 亞太地區的停經後骨質疏鬆症治療藥市場

第12章 市場推動要素

  • 老年人口的擴大
  • 停經後骨質疏鬆症的多發化
  • 預計有潛力開發平台分子的出現
  • 高度的未滿足醫療需求

第13章 推動要素的影響度

第14章 市場課題

  • 多數的專利失效
  • 低的診斷率
  • 治療計劃的不履行
  • 藥物報酬問題

第15章 推動要素及課題的影響度

第16章 市場趨勢

  • 自覺計劃及倡議
  • 新藥的出現
  • 複合治療的出現

第17章 商業環境

  • 競爭情形
  • 市場分析:2015年
  • Eli Lilly
  • Amgen
  • Merck
  • Novartis
  • 其他有力供給企業

第18章 附錄

  • 簡稱一覽

第19章 關於Technavio

目錄
Product Code: IRTNTR9271

About the Postmenopausal Osteoporosis Drugs Market

Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.

Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.

Technavio's analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • Amgen
  • Merck
  • Novartis

Other Prominent Vendors

  • Allergan
  • Amgen Astellas Biopharm
  • Deltanoid Pharmaceuticals
  • Noven
  • Novo Nordisk
  • Osteologix
  • Pfizer
  • PhytoHealth
  • Radius Health
  • Tarsa Therapeutics
  • UCB
  • Uni-Bio Science Group
  • Upsher-Smith Laboratories
  • Watson Pharmaceuticals
  • Zosano Pharma

Market driver

  • Growing prevalence of postmenopausal osteoporosis
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Emergence of novel agents
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding postmenopausal osteoporosis
  • Epidemiology and demography
  • Risk factors
  • Symptoms
  • Diagnosis
  • Treatment

PART 06: Key buying criteria

PART 07: Pipeline scenario

  • TBRIA
  • Romosozumab (AMG785)
  • Odanacatib (MK-0822)
  • Abaloparatide SC/Abaloparatide transdermal patch
  • PHN-031 (PH3)
  • NB S101
  • Teriparatide ZP Patch (ZP-PTH)
  • Blosozumab (LY2541546)

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by therapeutic class

  • Antiresorptive medications
  • Anabolic medications

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation

  • Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
  • Postmenopausal osteoporosis drugs market in Americas
  • Postmenopausal osteoporosis drugs market in EMEA
  • Postmenopausal osteoporosis drugs market in APAC

PART 12: Market drivers

  • Increase in older population
  • Growing prevalence of postmenopausal osteoporosis
  • Expected launch of promising pipeline molecules
  • High unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges

  • Multiple patent expiries
  • Low diagnosis rate
  • Nonadherence to treatment regimen
  • Drug reimbursement issues

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Awareness programs and initiatives
  • Emergence of novel agents
  • Emergence of combination therapies

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Eli Lilly
  • Amgen
  • Merck
  • Novartis
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Prevalence of osteoporosis based on gender 2015
  • Exhibit 03: Interpretation of BMD results
  • Exhibit 04: Timeline for development of osteoporosis drugs
  • Exhibit 05: Key buying criteria for postmenopausal osteoporosis drugs
  • Exhibit 06: Pipeline portfolio: Postmenopausal osteoporosis
  • Exhibit 07: Global postmenopausal osteoporosis drugs market 2015-2020 ($ billions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class
  • Exhibit 10: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class on basis of revenue 2015
  • Exhibit 11: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy
  • Exhibit 12: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy on basis of revenue 2015
  • Exhibit 13: Segmentation of global postmenopausal osteoporosis drugs market based on geography 2015
  • Exhibit 14: Global postmenopausal osteoporosis drugs market by geography 2015-2020 ($ billions)
  • Exhibit 15: Global postmenopausal osteoporosis drugs market by geography 2015-2020
  • Exhibit 16: Postmenopausal osteoporosis drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 17: Postmenopausal osteoporosis drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 18: Postmenopausal osteoporosis drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 19: Global postmenopausal osteoporosis drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 20: Percentage share of women in age group of 60 years and older 2015
  • Exhibit 21: Percentage share of women in age group of 80 years and above 2015
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of drivers and challenges
  • Exhibit 24: Revenue from sales of major drugs in global postmenopausal osteoporosis drugs market 2013-2015 ($ millions)
  • Exhibit 25: Eli Lilly: YoY revenue and growth rate of FORTEO 2015 ($ billions)
  • Exhibit 26: Eli Lilly: Geographical segmentation of FORTEO 2015
  • Exhibit 27: Eli Lilly: YoY revenue and growth rate of Evista 2015 ($ millions)
  • Exhibit 28: Eli Lilly: Geographical segmentation of Evista 2015
  • Exhibit 29: Eli Lilly: Key takeaways
  • Exhibit 30: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ millions)
  • Exhibit 31: Amgen: Geographical segmentation of Prolia 2015
  • Exhibit 32: Amgen: Key takeaways
  • Exhibit 33: Merck: YoY revenue and growth rate of Fosamax 2013-2015 ($ millions)
  • Exhibit 34: Merck: Key takeaways
  • Exhibit 35: Novartis: Key takeaways
Back to Top